 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...2122232425262728293031...6263» |
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Monitoring emerging HIV drug resistance in sub-Saharan Africa in the era of dolutegravir. (Pubmed Central) - May 11, 2022
To ensure its continued efficacy, monitoring of emerging drug resistance that inform a treatment strategy amongst those failing is crucial. Here we outline the plan by the President Emergence Plan for AIDS Relief to leverage viral load infra structure to implement effective drug resistance surveillance in the countries it supports.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: The evolving challenges confronting adults living with HIV in three North African countries during the COVID-19 crisis: a survey-based study. (Pubmed Central) - May 11, 2022
The pandemic adversely affected PLHIV. New innovative strategies should be implemented to ensure the continuity of HIV services.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Adherence to Antiretroviral Therapy and Associated Factors Among People Living With HIV Following the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania. (Pubmed Central) - May 10, 2022
Multivariate analysis found that patients attending care and treatment center (CTC) at Temeke Regional Referral Hospital (RRH) were 4.3 times more likely to have non-adherence compared to those attending Amana RRH (aOR [adjusted odds ratio] 4.3, 95% CI [confidence interval]: 2.38 - 7.91, p-value < 0.0001). Sustainable adherence counseling is warranted to overcome non-adherence to ART.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Moving forward with dolutegravir in children weighing less than 20 kg. (Pubmed Central) - May 7, 2022
Sustainable adherence counseling is warranted to overcome non-adherence to ART. No abstract available
- || Tivicay (dolutegravir) / ViiV Healthcare
P1/2 data, PK/PD data, Clinical Trial,Phase I, Journal: Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. (Pubmed Central) - May 7, 2022
P1/2
In this study, the proposed once daily dosing of dolutegravir dispersible tablets provided drug exposures similar to those for adults, and was safe and well tolerated. These data support the use of dolutegravir dispersible tablets as first-line or second-line treatment for infants and children aged less than 6 years living with HIV-1.
- | Tivicay (dolutegravir) / ViiV Healthcare
Preclinical, Journal: Dolutegravir and rat whole embryo culture. (Pubmed Central) - May 6, 2022
These data support the use of dolutegravir dispersible tablets as first-line or second-line treatment for infants and children aged less than 6 years living with HIV-1. No abstract available
- | Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study. (Pubmed Central) - May 6, 2022
No abstract available Dolutegravir-based 2DR showed high virological efficacy and durability, however past resistance increased the risk of VF, but not of TD or TF.
- || Tivicay (dolutegravir) / ViiV Healthcare
PK/PD data, Journal, Head-to-Head: Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. (Pubmed Central) - May 6, 2022
Weight-band dosing of paediatric dolutegravir dispersible tablets provides appropriate drug exposure in most children weighing 3 kg to less than 20 kg, with no safety signal. 25 mg film-coated tablets did not achieve pharmacokinetic parameters in children weighing 14 kg to less than 20 kg, which were comparable to adults, suggesting dosing with dispersible tablets is preferable or a higher film-coated tablet dose is required.
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes. (Pubmed Central) - May 6, 2022
The LDL-fraction increased by + 13.3 (-3.0 to +31.3) mg/dL on 2DRs and was stable (-14.0 to +18.0 mg/dL) on 3DRs (p < 0.0010).PLWH gained +2.0 (-0.2 to +4.0) kg and +0.2 (-1.9 to +2.1) kg in body weight on 2DRs and 3DRs, respectively 3 (p = 0.0006).The MDRD eGFR decreased by -7,8 (-17.4 to -0.3) mL/min/1.73m and 0.4 (-8.8 to +5.7) mL/min/1.73m on 2DRs and 3DRs, respectively (p = 0.0002), while serum levels of cystatin C were stable in both arms (2DR: -0.1 to +0.1 mg/L; 3DR: 0.0 to +0.1 mg/L). While being non-inferior in terms of viral suppression, sparing the NRTI backbone showed a non-favorable profile in metabolic or renal parameters over 48 weeks.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Dolutegravir Resistance in Malawi's National HIV Treatment Program. (Pubmed Central) - May 3, 2022
Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.
- ||||| darunavir/ritonavir / Generic mfg., Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Clinical: More evidence that second-line dolutegravir is not inferior to ritonavir-boosted darunavir: https://t.co/el9GPag5M6 #HIV #IDTwitter @CarlosdelRio7 (Twitter) - May 3, 2022
- ||| darunavir/ritonavir / Generic mfg., Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Review: More Evidence That Second-Line Dolutegravir Is Not Inferior to Ritonavir-Boosted Darunavir. Here is my review and comment in @JWatch on the 96 wk data on the NADIA study published in @TheLancetHIV https://t.co/wKCWzxiqRK (Twitter) - May 2, 2022
- || Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
Enrollment closed, Combination therapy: DOMINO: A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults (clinicaltrials.gov) - May 2, 2022
P2b, N=150, Active, not recruiting, Sponsor: ViiV Healthcare
Malawi urgently requires adequate HIVDR testing capacity. Recruiting --> Active, not recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
Observational data, Retrospective data, Journal: Incidence and Predictors of Loss to Follow Up among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study. (Pubmed Central) - Apr 30, 2022
An ART program in such a setting should pay more attention to naive patients and other particularly vulnerable patients such as Sudanese during the pre-ART phase. The study implies the implementation of innovative strategies to address this high risk of being LTFU, reducing either the cost or the distance to the health facility.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia. (Pubmed Central) - Apr 30, 2022
Our results support the implementation of a wide scale-up of dolutegravir-based regimes. However, the detection of polymorphisms contributing to INSTI warrants the continuous surveillance of INSTI resistance.
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Journal: Reduction of CD8 T cell functionality but not inhibitory capacity by integrase inhibitors. (Pubmed Central) - Apr 29, 2022
In summary, our study provides first evidence on a significant, negative impact on CD8 T cell effector functions in the presence of two INSTIs, dolutegravir and elvitegravir, which may contribute to the limited success of eradicating HIV-infected cells through "shock-and-kill" strategies. Although our findings are coherent with recent studies highlighting a possible role of dolutegravir in weight gain, further investigations are necessary to fully understand the impact of INSTI-based regimens on the health of the individual during antiretroviral therapy.
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Review, Journal, Adverse events: In utero exposure to antiretroviral drugs and pregnancy outcomes: analysis of the French ANRS pharmacovigilance database. (Pubmed Central) - Apr 27, 2022
Our study, mainly based on PI and NNRTI-based regimens, is overall reassuring on the risk of adverse pregnancy outcomes, except for NRTI which should be interpreted cautiously (small number, indication bias). In this study, the number of INI-based combinations were too low to draw any conclusions.
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: RADIANT-TB: Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis (clinicaltrials.gov) - Apr 26, 2022
P2, N=108, Active, not recruiting, Sponsor: University of Cape Town
In this study, the number of INI-based combinations were too low to draw any conclusions. Recruiting --> Active, not recruiting
- Tivicay (dolutegravir) / ViiV Healthcare
EFFICACY AND SAFETY OF PAN-GENOTYPIC SOFOSBUVIR AND VELPATASVIR IN PATIENTS WITH CHRONIC HEPATITIS C AND HIV CO-INFECTION ON DOLUTEGRAVIR BASED ANTI-RETROVIRAL THERAPY (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_950;
No grade III/IV adverse events were reported and there was no worsening of hemogram, liver or renal function test parameters during treatment. Conclusion :The pan-genotypic regimen of S+V is safe and effective in PLHA with HCV co-infection who are on TLD.
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Journal: Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection. (Pubmed Central) - Apr 24, 2022
Not statistically significant factors associated with LL-HIVDNA achievement were found, whereas a higher baseline CD4/CD8 ratio predicted the achievement of immune recovery. In PHI patients, the rapid initiation of either an intensified four-drug or a standard three-drug INSTI-based regimen showed comparable responses in terms of VS, viral reservoir size, and immunological recovery.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Weight gain during the dolutegravir transition in the African Cohort Study. (Pubmed Central) - Apr 21, 2022
Elevated BMI and weight gain among PLWH on TLD are concerning safety signals. Implications for the development of metabolic comorbidities should be monitored, particularly if annual weight gain persists during continued follow-up after transitioning to TLD.
- | Intelence (etravirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. (Pubmed Central) - Apr 19, 2022
Both Etravirine and Dolutegravir showed similar neutralizing activities against different variants, with EC50 values between 4.5 to 5.8 nM for Etravirine and 10.2 to 22.9 nM for Dolutegravir. These data implied that Etravirine and Dolutegravir may serve as general spike inhibitors against dominant viral variants of SARS-CoV-2.
- | Tivicay (dolutegravir) / ViiV Healthcare
Biomarker, Journal: Comparison of Renal Function Biomarkers of Serum Creatinine and Cystatin C in HIV-Infected People on Dolutegravir-Containing Therapy. (Pubmed Central) - Apr 19, 2022
Moreover, the proportion of eGFRcr decreased over 30% was significantly higher in DTG-treatment group. We demonstrated the clinical benefits of CysC for assessing the glomerular filtration rate when evaluating renal function in HIV-1-infected patients treated with whether DTG combined with TDF or not.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Pretreatment Human Immunodeficiency Virus (HIV) Drug Resistance Among Treatment-Naive Infants Newly Diagnosed With HIV in 2016 in Namibia: Results of a Nationally Representative Study. (Pubmed Central) - Apr 19, 2022
The absence of resistance to dolutegravir (DTG) is reassuring but underscores the need to further study the impact of ABC and 3TC/FTC resistance on pediatric protease inhibitor- and DTG-based regimens and accelerate access to other antiretroviral drugs. Results underscore the need for antiretroviral therapy optimization and prompt management of high viral loads in infants and pregnant and breastfeeding women.
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort. (Pubmed Central) - Apr 12, 2022
Results underscore the need for antiretroviral therapy optimization and prompt management of high viral loads in infants and pregnant and breastfeeding women. In the real world, the risks of discontinuation due to TF and VF were more than two times higher in patients switching to DTG-based 2DR than INSTI-based 3DR, with no difference in discontinuation due to AEs.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor based regimens in children and adolescents in Kenya. (Pubmed Central) - Apr 9, 2022
We observed high-levels of viral suppression among those on tenofovir-lamivudine-dolutegravir even in presence of an inactive NRTI backbone, but lower levels among those on protease-inhibitors especially those retained on an inactive abacavir. While tenofovir may be recycled with dolutegravir, more studies are needed to determine if abacavir can be reused with dolutegravir or protease-inhibitors.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: CONCENTRATION-RESPONSE RELATIONSHIPS OF DOLUTEGRAVIR AND EFAVIRENZ WITH WEIGHT CHANGE AFTER STARTING ANTIRETROVIRAL THERAPY. (Pubmed Central) - Apr 9, 2022
Dolutegravir concentrations were not independently associated with weight change. These findings suggest that weight gain differences between efavirenz and dolutegravir are driven by efavirenz toxicity impairing weight gain rather than by off-target effects of dolutegravir causing weight gain.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: The risk of hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala, Uganda: a case-control study. (Pubmed Central) - Apr 8, 2022
Our study shows a strong association between previous dolutegravir exposure and hyperglycaemia. Given the benefits of dolutegravir, its wide-scale roll-out in sub-Saharan Africa, and the growing burden of diabetes, systematic screening of hyperglycaemia before initiation of dolutegravir, routine glucose monitoring, and the consideration of alternate regimens for those at risk for diabetes are needed.
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Journal, Adverse events: Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study. (Pubmed Central) - Apr 5, 2022
Male sex, early HIV disease stage at entry into care and detectable viral load at initiation of DTG-based regimen were significantly associated with ADEs. It is crucial to actively monitor patients with these characteristics for ADEs.
- | bictegravir (GS-9883) / Gilead
Journal: First report of computational protein-ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients. (Pubmed Central) - Apr 5, 2022
Several analyses were performed including docking screening, genotypic resistance, secondary/tertiary structures, post-translational modification (PTM), immune epitopes, etc. The average docking energy (E value) of different samples with elvitegravir (EVG) and raltegravir (RAL) was more than other INTIs...Some conserved motifs and specific amino acids in INT-protein binding sites have characterized that mutation(s) in them may disrupt INT-drugs interaction and cause a significant loss in susceptibility to INTIs. Good adherence, treatment of naïve patients, and monitoring injection drug users are fundamental factors to control HIV infection in Iran effectively.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: In-silico drug repurposing for targeting SARS-CoV-2 main protease (M). (Pubmed Central) - Apr 2, 2022
Further, in silico docking and MD simulation suggest that EGCG analogues ZINC21992196 and ZINC 169337541 may act as a better inhibitor. Communicated by Ramaswamy H. Sarma.
- || Tivicay (dolutegravir) / ViiV Healthcare
PK/PD data, Preclinical, Journal: Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice. (Pubmed Central) - Apr 2, 2022
Tissue specificity was also observed, with strong penetration of the digestive tract and weak penetration of the brain. These data have important implications for future preclinical and clinical studies for developing new HIV therapies with the goal of an HIV cure.
- | bictegravir (GS-9883) / Gilead
Journal: Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. (Pubmed Central) - Apr 2, 2022
High-level dolutegravir, bictegravir and cabotegravir resistance requires multiple integrase substitutions including compensatory mutations. T97A and E138K further enhance the resistance conferred by G140S/Q148H, yielding >300-fold decreased susceptibility to all INSTIs when all four mutations are present.
- | Tivicay (dolutegravir) / ViiV Healthcare
Preclinical, Journal: Interaction between dolutegravir and folate transporters and receptor in human and rodent placenta. (Pubmed Central) - Apr 1, 2022
T97A and E138K further enhance the resistance conferred by G140S/Q148H, yielding >300-fold decreased susceptibility to all INSTIs when all four mutations are present. These findings demonstrate a potential interaction between DTG and folate transport pathways in the placenta, particularly in vivo, under folate deficient conditions, potentially impacting folate delivery to the foetus in the context of DTG-based ART during pregnancy.
- ||| Prezcobix (darunavir/cobicistat) / Gilead, J&J, Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Trial completion date, Trial primary completion date: EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS (clinicaltrials.gov) - Apr 1, 2022
P4, N=96, Completed, Sponsor: Fundaci
These findings demonstrate a potential interaction between DTG and folate transport pathways in the placenta, particularly in vivo, under folate deficient conditions, potentially impacting folate delivery to the foetus in the context of DTG-based ART during pregnancy. Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Aug 2021 | Trial primary completion date: Jun 2023 --> Aug 2021
- || Tivicay (dolutegravir) / ViiV Healthcare
PK/PD data, Journal: Effects of Injection Volume and Route of Administration on Dolutegravir In Situ Forming Implant Pharmacokinetics. (Pubmed Central) - Mar 27, 2022
ISFI release kinetics best fit to zero order or diffusion-controlled models. When total administered dose was held constant, there was no statistical difference in drug exposure regardless of the route of administration or number of injections.
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Many congratulations @LoosliTom for winning at #IWHOD2022 the young investigator award for the best talk on the Dolutegravir Resistance Cohort Collaboration with @eggersnsf @uzh_evolution @iedea_sa @UZH_Virology @HGunthard @HivSwiss ART-CC and many others (Twitter) - Mar 27, 2022
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal, Adverse events: The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV. (Pubmed Central) - Mar 26, 2022
Treatment-associated obesity increased the APO risk in women. This risk is likely to increase, as preliminary data from ADVANCE demonstrate ongoing weight gain beyond 96 weeks.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: HIV-1 drug resistance and genetic diversity in a cohort of people living with HIV-1 in Nigeria. (Pubmed Central) - Mar 26, 2022
Our study also further emphasizes the high genetic diversity of HIV-1 in Nigeria and that CRF02_AG and subtype G are the dominant circulating forms of HIV-1 in Nigeria. These two circulating forms of the virus are largely driving the epidemic in the country.
- || Vocabria (cabotegravir oral) / ViiV Healthcare
Clinical, Journal: Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results. (Pubmed Central) - Mar 26, 2022
P2b
CAB+RPV long-acting maintained virologic suppression in participants who had previously received daily oral CAB+RPV for at least 5 years in LATTE, with a favorable safety profile. Most participants preferred CAB+RPV long-acting to their prior oral CAB+RPV regimen at M12.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. (Pubmed Central) - Mar 26, 2022
In this review, we examine the data from these studies to consider the contributions of adherence and HIV drug resistance to treatment failure on DTG-based ART, as compared with efavirenz (EFV)-based ART, which has a lower genetic barrier to resistance. We also discuss the implications of virologic failure on DTG and consolidate currently available data to conclude with recommendations for virologic monitoring on DTG-based ART.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Accelerating access and scale-up of optimized antiretroviral therapy in low-income and middle-income countries: results of a coordinated end-to-end approach. (Pubmed Central) - Mar 26, 2022
The global HIV community invested in multiple, high-profile partnerships and shepherded unprecedented political support to expedite the transition to dolutegravir (DTG)-based regimens...This approach of planning with the 'end-in-mind' - and the belief that this end-to-end mindset can facilitate healthy markets, catalyze the application of new health technologies, and accelerate the development of improved products - is increasingly being applied across HIV prevention, care, and treatment (e.g. for biomedical prevention), and across health sectors (e.g. in maternal and child health, food security and water, and sanitation). This review of antiretroviral treatment (ART) optimization efforts from 2015 through 2020 discusses what worked, what is next, and how the learnings from HIV treatment can inform the broader global health community looking for innovative partnership models to accelerate adoption and enable scale-up of promising new products and programs.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal, HEOR: Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. (Pubmed Central) - Mar 26, 2022
This review of antiretroviral treatment (ART) optimization efforts from 2015 through 2020 discusses what worked, what is next, and how the learnings from HIV treatment can inform the broader global health community looking for innovative partnership models to accelerate adoption and enable scale-up of promising new products and programs. TDF/FTC+DTG had similar costs per outcome as TDF/FTC/EFV in the routine care scenario but TDF/FTC+DTG was more cost-effective when modelled over 20 years.
- | Tivicay (dolutegravir) / ViiV Healthcare
Preclinical, Journal: Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment. (Pubmed Central) - Mar 25, 2022
These abnormalities persist as a consequence of in utero DTG exposure. We conclude that DTG inhibition of MMPs activities during gestation has the potential to affect prenatal and postnatal neurodevelopment.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal, HEOR: Patient-Reported Treatment Satisfaction and Quality of Life Among People Living with HIV Following the Introduction of Dolutegravir-Based ART Regimens in Ukraine. (Pubmed Central) - Mar 25, 2022
Also in adjusted analyses, unemployment, low income, and history of injection drug use were associated with unfavorable PROs. While the results indicate modestly favorable effects of ART Optimization, there is clearly a need for complementary interventions to improve PROs among disadvantaged ART patients in Ukraine.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Dolutegravir impairs stem cell-based 3D morphogenesis models in a manner dependent on dose and timing of exposure: an implication for its developmental toxicity. (Pubmed Central) - Mar 24, 2022
These studies demonstrate that dolutegravir impairs morphological and molecular aspects of the in vitro morphogenesis models in a manner dependent on dose and timing of exposure through mechanisms that are unrelated to its action as an integrase strand transfer inhibitor. This finding will be useful for interpreting the conflicting outcomes regarding the developmental toxicity of dolutegravir in human and animal studies.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Mutations in the HIV-1 3'-polypurine tract can confer dolutegravir resistance. (Pubmed Central) - Mar 23, 2022
This finding will be useful for interpreting the conflicting outcomes regarding the developmental toxicity of dolutegravir in human and animal studies. With interest we read the Letter to the Editor of Wei and Sluis-Cremer about the role of human immunodeficiency virus 1 (HIV-1) 3'polypurine tract (3'PPT) mutations in dolutegravir (DTG) resistance 1.….
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study. (Pubmed Central) - Mar 23, 2022
P3b
Overall, among treatment-experienced adults who received dolutegravir in DAWNING, 6 of 314 participants developed treatment-emergent INSTI resistance-associated substitutions, with in vitro dolutegravir resistance >10 fold-change and reduced viral replication capacity vs baseline levels. This study demonstrates that the pathway to dolutegravir resistance is a challenging balance between HIV-1 phenotypic change and associated loss of viral fitness (ClinicalTrials.gov identifier: NCT02227238).
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Emergence of Resistance in HIV-1 Integrase With Dolutegravir Treatment in a Pediatric Population From the IMPAACT P1093 Study. (Pubmed Central) - Mar 23, 2022
P1/2
G118R or R263K INSTI resistance substitutions, which are distinct to second-generation INSTIs, were detected in adolescents and children with prior virologic failure who received dolutegravir. This study provides additional molecular and structural characterization of integrase to aid in the understanding of INSTI resistance mechanisms in antiretroviral-experienced populations (ClinicalTrials.gov identifier: NCT01302847).
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: An eco- friendly, selective, and sensitive spectrofluorimetric method for the quantification of Dolutegravir in its bulk and tablet dosage form. (Pubmed Central) - Mar 23, 2022
The results of the proposed method were compared with those obtained by applying the comparison method and the two sets coincided harmoniously. In addition, the method was validated in accordance with ICH guidelines for linearity, accuracy, precision, specificity, and robustness.